The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference47 articles.
1. Chronic myelogenous leukaemia: biology and therapy;Faderl;Ann Intern Med,1999
2. Chronic myeloid leukaemia-advances in biology and new approaches to treatment;Goldman;N Engl J Med,2003
3. Molecular mechanisms of transformation by the BCR-ABL oncogene;Sattler;Semin Hematol,2003
4. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukaemia cells selected for resistance to STI571;Donato;Blood,2003
5. The development of imatinib as a therapeutic agent for chronic myeloid leukemia;Deininger;Blood,2005
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy;Leukemia;2022-06-01
2. An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia;Current Medical Research and Opinion;2021-04-02
3. Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge;Journal of Clinical Medicine;2021-02-01
4. Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?;Haematologica;2019-04-30
5. Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved;International Journal of Hematology;2017-10-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3